Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3

Status

Completed 6Terminated 5Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 2Thoracic 1Other 1NET 1Head & Neck 1Gynecologic 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Lymphoma 2Stomatitis 1Neuroendocrine Tumors 1Neoplasms 1Mucositis 1Mouth Neoplasms 1Lung Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × INDUSTRY × RRx-001 × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT03515538 2024-11-04

PREVLAR

EpicentRx, Inc.

Phase 2 Completed
53 enrolled 15 charts
Head & NeckOther

Head and Neck Neoplasms, Mouth Neoplasms, Stomatitis, Mucositis

NCT01359982 2024-11-01

DINAMIC

EpicentRx, Inc.

Phase 1 Completed
26 enrolled 11 charts
Lymphoid

Lymphoma, Neoplasms

NCT02096354 2024-10-15

ROCKET

EpicentRx, Inc.

Phase 2 Completed
62 enrolled 14 charts
Gastrointestinal

Colorectal Neoplasms

NCT02215512 2021-11-03

BRAINSTORM

EpicentRx, Inc.

Phase 1 Completed
29 enrolled
CNS

Brain Neoplasms

NCT02518958 2019-11-18

PRIMETIME

EpicentRx, Inc.

Phase 1 Completed
12 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡